NeoGenomics (NEO) Q1 2026 earnings review
Quality Over Quantity: Mix Shift Drives Earnings Amid Volume Reset
NeoGenomics delivered a solid Q1 2026, demonstrating that its strategic pivot from high-volume/low-value testing to a high-margin product mix is working. Consolidated revenue grew 11% YoY to $187 million, while net loss narrowed by 34% to $17 million. A major underlying story is the sequential drop in clinical test volumes (-3% vs Q4 2025), which was fully offset by an accelerating Average Unit Price (AUP) that reached $495. With the full clinical launch of the RaDaR ST MRD assay and a crucial MolDX coverage decision for PanTracer LBx secured, the company narrowed its FY26 revenue guidance upward, reflecting confidence in its high-value testing portfolio.
🐂 Bull Case
Average revenue per test accelerated to $495 (+8% YoY), proving the company can successfully shed low-margin contracts and replace them with higher-value therapy selection and MRD volume without destroying top-line growth.
Favorable MolDX coverage for PanTracer LBx (liquid biopsy) removes a massive commercial overhang, while the full launch of RaDaR ST opens a $20 billion addressable market.
🐻 Bear Case
Clinical test volumes fell sequentially from 356k in 25Q4 to 345k in 26Q1. While intentional, sustained volume contraction reduces overall lab utilization and fixed-cost leverage.
Non-clinical revenue remains a chronic weak point, dampening overall top-line performance despite the strength in the core clinical franchise.
⚖️ Verdict: 🟢
Bullish. The company is doing exactly what it promised: swapping empty volume for profitable growth. The narrowing net loss, positive EBITDA, and critical regulatory milestones for PanTracer LBx provide a clear runway for the rest of FY26.
Key Themes
Strategic Mix Shift Drives AUP Acceleration
Management's deliberate strategy to exit low-value contracts (e.g., $200 AUP deals) in favor of high-value NGS and MRD testing is accelerating. Average revenue per clinical test reached $495 in 26Q1, up 8% YoY and up sequentially from $488 in 25Q4. This shift directly fueled the 14% YoY growth in clinical revenue despite a moderation in volume growth.
PanTracer LBx Secures Vital Reimbursement
NeoGenomics announced a favorable MolDX coverage decision for PanTracer LBx, its blood-based comprehensive genomic profiling test. This was previously flagged as a major overhang and a gating factor for 2026 revenue. The concurrent launch of PanTracer Pro aims to streamline complex molecular workflows, heavily arming the sales force to capture community oncology market share.
RaDaR ST Full Clinical Launch Initiated
The company officially executed the full clinical launch of the RaDaR ST (ctDNA) assay for molecular residual disease (MRD) in February. Targeting an estimated $20 billion, under-penetrated addressable market, this launch shifts RaDaR from an R&D milestone to a primary commercial growth engine for FY26 and beyond.
Clinical Volume Decelerating Sequentially
While total tests performed grew 6% YoY, volume sequentially declined from 356,136 in 25Q4 to 345,679 in 26Q1. Management previously telegraphed this as a consequence of exiting low-value contracts and Q1 weather impacts, but the absolute decline requires monitoring to ensure the core clinical franchise isn't losing broader market share.
Persistent Drag from Non-Clinical Segment
While clinical revenue grew 14%, consolidated revenue grew only 11%, highlighting the ongoing weakness in the non-clinical (pharma services) business. Implied non-clinical revenue for 26Q1 is approximately $15.5 million, down from ~$18.3 million in 25Q1. This segment continues to dilute the company's overall growth profile.
Other KPIs
Accelerating. Up 27% from $7.1M in the prior year quarter. The margin improvement reflects the company's ability to hold operating expenses relatively flat ($99.1M, down 2% YoY) while growing top-line revenue by $18.6M.
Improving but still negative. Operating cash flow was -$8.1M and CapEx was -$5.0M. This is a significant improvement from the -$29.8M cash burn in 25Q1, but achieving management's goal of becoming free cash flow positive in FY26 will require a steep ramp in the second half of the year. Total cash and marketable securities sit at $146M.
Stable. Gross margin was slightly down from 43.6% in 25Q1, driven by higher overall cost of revenue. However, Adjusted Gross Profit Margin (excluding amortization and stock-based compensation) came in at 46.0%, providing a solid baseline for profitability as high-margin testing volume scales.
Guidance
Stable/Accelerating. The company raised the bottom end of its previous guidance ($793M - $801M). The midpoint of $800M implies exactly 10% YoY growth compared to FY25 actuals ($727M), signaling confidence in the PanTracer and RaDaR launches overcoming the volume drop from low-value contract exits.
Stable. The company reiterated its initial FY26 adjusted EBITDA guidance. The midpoint ($56M) implies a robust 30% YoY growth rate over FY25 ($43M), heavily relying on sustained gross margin expansion and AUP growth in H2 2026.
Stable. Reiterated guidance implies a significant 42% to 54% reduction in net loss compared to the -$108M recorded in FY25, indicating the company is successfully outgrowing its fixed cost base and past impairment charges.
Key Questions
PanTracer LBx Revenue Ramp
With the favorable MolDX coverage decision now secured for PanTracer LBx, how quickly do you expect this to translate into recognized revenue, and what does the commercial payer adoption curve look like for the remainder of 2026?
Path to Positive Free Cash Flow
Q1 saw a derived free cash burn of approximately $13M. Given the stated goal of becoming FCF positive in 2026, is this expected to be achieved on a full-year basis, or merely crossing the threshold in Q3/Q4?
Pharma Services Stabilization
The implied non-clinical revenue continues to drag overall growth. What specific catalysts or new product offerings (such as RaDaR ST for biopharma) are needed to stabilize this segment and return it to growth?
Volume Floor
Clinical volumes declined sequentially as you actively exited lower-value contracts. Have we reached the bottom of this intentional volume shedding, and should we expect sequential volume growth to resume in Q2?